Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...